HC Wainwright Equities Analysts Decrease Earnings Estimates for Celcuity Inc. (NASDAQ:CELC)

Celcuity Inc. (NASDAQ:CELC) – Analysts at HC Wainwright reduced their FY2028 earnings estimates for shares of Celcuity in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $4.08 for the year, down from their previous estimate of $4.51. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($2.93) per share.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, March 27th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.06.

Other research analysts also recently issued reports about the stock. Stifel Nicolaus reissued a “buy” rating and issued a $40.00 price target on shares of Celcuity in a report on Thursday. Craig Hallum reaffirmed a “buy” rating and set a $27.00 price objective (up from $25.00) on shares of Celcuity in a report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celcuity in a report on Thursday.

Celcuity Stock Performance

NASDAQ:CELC traded down $0.19 during trading hours on Friday, hitting $17.47. The stock had a trading volume of 12,455 shares, compared to its average volume of 215,247. The company has a 50 day simple moving average of $17.99 and a two-hundred day simple moving average of $15.58. The company has a quick ratio of 13.43, a current ratio of 13.43 and a debt-to-equity ratio of 0.26. Celcuity has a one year low of $8.39 and a one year high of $22.19.

Institutional Trading of Celcuity

Hedge funds have recently made changes to their positions in the stock. Trust Point Inc. bought a new stake in shares of Celcuity during the 4th quarter worth $297,000. SG Americas Securities LLC purchased a new position in Celcuity in the 4th quarter worth $139,000. Pale Fire Capital SE purchased a new position in Celcuity in the 3rd quarter worth $95,000. Vanguard Group Inc. raised its position in Celcuity by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after purchasing an additional 7,821 shares during the period. Finally, Baker BROS. Advisors LP raised its position in Celcuity by 189.9% in the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock worth $33,534,000 after purchasing an additional 1,017,000 shares during the period. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.